Click image to enlargeCentanafadine is a non-stimulant, triple reuptake inhibitor that modulates norepinephrine, dopamine and serotonin reuptake with the intent of improving focus, attention, and specific higher level cognitive skills in patients with ADHD. Two phase II clinical trials in adults, including a phase IIb trial, have been completed for centanafadine, setting the stage for the start of phase III trials in ADHD.
It can take up to 28 days for your study doctor to confirm you are eligible to join the study. Everyone in this study will get centanafadine and/or placebo (a pill without active medicine, sometimes called a “sugar pill”). In this informed consent, centanafadine and placebo will be referred to as “study drug.” Once you are assigned to a study treatment, you will remain on that treatment for the whole treatment period of 49 days. Out of approximately 450 people:
· Approximately 150 will receive centanafadine SR 200mg
· Approximately 150 will receive centanafadine SR 400mg
· Approximately 150 will receive placebo